key: cord-0957166-gm0qhfjt
authors: Levi, Marcel; Hunt, Beverley J.
title: Thrombosis and coagulopathy in COVID‐19: An illustrated review
date: 2020-07-11
journal: Res Pract Thromb Haemost
DOI: 10.1002/rth2.12400
sha: b774cfe1fa8ef2583dc7b4fb87bb5976132a5fc2
doc_id: 957166
cord_uid: gm0qhfjt

This illustrated review discusses the haemostatic changes seen in patients with severe coronavirus disease 2019 (COVID‐19) infection and their possible causes. We discuss the crosstalk between inflammation and coagulation resulting in high levels of acute‐phase proteins, very high levels of D‐dimers, and absence of disseminated intravascular coagulation seen in patients with severe COVID‐19. There appear to be high rates of venous thromboembolism and also, what has been poorly described before in acute lung injury, a high rate of pulmonary immunothrombosis (thrombosis secondary to inflammation).

Beverley J. Hunt @bhwords

Clinical characteristics of coronavirus disease 2019 in China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Disseminated intravascular coagulation

Disseminated intravascular coagulation

Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation

A re-evaluation of the D-dimer cut-off value for making a diagnosis according to the ISTH overt-DIC diagnostic criteria: communication from the SSC of the ISTH

The pulmonary physician in critical care: The pathogenesis of ALI/ARDS

COVID-19: consider cytokine storm syndromes and immunosuppression

Bidirectional relation between inflammation and coagulation

Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury

Elevated plasma tissue-type plasminogen activator (t-PA) and soluble thrombomodulin in patients suffering from severe acute respiratory syndrome (SARS) as a possible index for prognosis and treatment strategy

Plasmin and matrix metalloproteinases in vascular remodeling

Pulmonary and cardiac pathology in Covid-19: The first autopsy series from New Orleans

COVID-19 complicated by acute pulmonary embolism

Venous thromboembolism prophylaxis in critically ill patients

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

ISTH interim guidance on recognition and management of coagulopathy in COVID-19